Business Context and Reporting Period
This Form 8-K is filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on November 13, 2012. The report announces the financial results for the quarter ended September 30, 2012. The detailed financial data is contained in a press release furnished as Exhibit 99.1, which is not included in the provided text.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1), but the text of that exhibit is not present in the source material.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the announcement of the third-quarter fiscal 2012 results.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risks, or contingencies. It explicitly states that the information in this report (including the press release) is furnished and not "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the correct registrant name is OvaScience, Inc., as the request metadata incorrectly listed "Tempest Therapeutics, Inc."
- Locate and review Exhibit 99.1 (Press Release dated November 13, 2012) to obtain actual financial figures for the quarter ended September 30, 2012.
- Confirm the specific revenue and cash burn rates, as these are critical for a biotechnology firm but are absent from the 8-K summary text.
- Check for any subsequent filings that may have incorporated the press release by reference.